CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Treasury Stock	Accumulated Deficit	Accumulated Other Comprehensive Loss	Total UpHealth, Inc. Stockholders’ Equity	Noncontrolling Interests
Balance at beginning of period (in shares) at Dec. 31, 2021		14,428,000
Balance at beginning of period at Dec. 31, 2021	$ 333,843	$ 1	$ 665,474	$ 0	$ (343,209)	$ (3,802)	$ 318,464	$ 15,379
Balance at beginning of period (in shares) at Dec. 31, 2021				0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Equity award activity, net of shares withheld for taxes (in shares)		681,000
Equity award activity, net of shares withheld for taxes	(1,295)	$ 1	(1,296)				(1,295)
Issuance of common stock (in shares)		115,000
Issuance of common stock	713		713				713
Stock-based compensation	6,464		6,464				6,464
Common stock repurchased in connection with forward share purchase agreement (in shares)		(170,000)		170,000
Common stock repurchased in connection with forward share purchase agreement	0		17,000	$ (17,000)
Purchase of noncontrolling interest	(31)							(31)
Distributions to noncontrolling interests	(139)							(139)
Deconsolidation of subsidiary	(14,285)							(14,285)
Net loss	(222,935)				(223,000)		(223,000)	65
Foreign currency translation adjustments	$ 3,802					3,802	3,802
Balance at end of period (in shares) at Dec. 31, 2022	15,054,431	15,054,000
Balance at end of period at Dec. 31, 2022	$ 106,137	$ 2	688,355	$ (17,000)	(566,209)	0	105,148	989
Balance at end of period (in shares) at Dec. 31, 2022				170,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Equity award activity, net of shares withheld for taxes (in shares)		617,000
Equity award activity, net of shares withheld for taxes	(100)		(100)				(100)
Issuance of common stock (in shares)		1,650,000
Issuance of common stock	4,155		4,155				4,155
Exercise of pre-funded warrants (in shares)		1,350,000
Stock-based compensation	3,740		3,740				3,740
Distributions to noncontrolling interests	(955)							(955)
Deconsolidation of subsidiary	(1,457)							(1,457)
Net loss	(56,416)				(57,839)		(57,839)	1,423
Foreign currency translation adjustments	$ 0
Balance at end of period (in shares) at Dec. 31, 2023	18,671,142	18,671,000
Balance at end of period at Dec. 31, 2023	$ 55,104	$ 2	$ 696,150	$ (17,000)	$ (624,048)	$ 0	$ 55,104	$ 0
Balance at end of period (in shares) at Dec. 31, 2023				170,000